| Name | Title | Contact Details |
|---|---|---|
Jackie Marks |
VP | Head, Enterprise Inspection Readiness & Operational Compliance | Profile |
Susan Hensley |
Senior Director, Regulatory Operations Regulatory Affairs Vaccines | Profile |
Tatiana Ishida |
Vice President, Head of Regulatory Affairs Marketed Products and Global Labeling | Profile |
Patrick Eagleman |
VP, Intellectual Property | Profile |
Michelle Kliewer |
Vice President Global Regulatory Affairs GI | Profile |
Qualyst is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Octamer is a Belvedere Tiburon, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Altegra Health is a national provider of technology-enabled, end-to-end payment solutions that enable health plans and other risk-bearing organizations to generate, analyze and submit the data needed to successfully manage member care and ensure appropriate reimbursement. The power of Altegra Health’s advanced analytics and supporting interventions enables healthcare organizations to elevate care quality, optimize financial performance, and enhance the member experience.
Dicerna is working to improve the lives of people suffering from rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. We discover and develop innovative therapies to stop or turn off destructive disease processes by silencing the genes underlying these processes. Our proprietary, next-generation technology, GalXC™, is a platform that uses the body`s natural biological pathways to silence genes in the liver with a high degree of selectivity and specificity. By targeting genes that contribute to serious diseases, we seek to address the underlying cause of illness and restore health. We have qualified dozens of disease-associated genes in clinical indications where we believe an RNAi-based inhibitor may provide substantial benefit to patients, providing expansive therapeutic opportunities. Dicerna is advancing a growing pipeline of product candidates based on our GalXC platform to deliver transformative therapies to patients. Dicerna brings together talented experts in biology, chemistry, clinical science and medicine. With decades of scientific and technical experience focused on RNAi technology, our team has the knowledge and experience needed to discover, develop and commercialize safe and effective therapies for patients with serious unmet medical needs. Our purpose is clear: delivering life-changing therapies as efficiently as possible to meet the urgent needs of people living with debilitating genetic diseases.